The next generation of gene therapy for rare diseases forges ahead as developers weather hurdles
Dec 14, 2020 5:28am Questions about how long gene therapies can exert their effects in the body have encouraged several companies to find new ways to make the treatments more durable. (Photo by kirstypargeter/iStock/Getty Images Plus/Getty Images) When gene therapy developer Generation Bio raised $110 million in venture funding in January and then followed up six months later with a $230 million initial public offering, it was as sure a sign as any that investors are stoked about the next generation of gene therapies to treat rare diseases. Their enthusiasm hasn’t waned during the ...
Source: fiercebiotech.com